US 12,215,167 B2
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
Jan-Willem Theunissen, South San Francisco, CA (US); Andrew D. Avery, South San Francisco, CA (US); Allen G. Cai, South San Francisco, CA (US); Anthony Byron Cooper, South San Francisco, CA (US); and Thi-Sau Migone, South San Francisco, CA (US)
Assigned to ICONIC THERAPEUTICS LLC, Palo Alto, CA (US)
Filed by Iconic Therapeutics LLC, Palo Alto, CA (US)
Filed on Jul. 29, 2022, as Appl. No. 17/877,853.
Application 17/877,853 is a division of application No. 17/458,507, filed on Aug. 26, 2021, granted, now 11,447,566.
Application 17/458,507 is a continuation of application No. 16/959,652, abandoned, previously published as PCT/US2019/012427, filed on Jan. 4, 2019.
Claims priority of provisional application 62/713,797, filed on Aug. 2, 2018.
Claims priority of provisional application 62/713,804, filed on Aug. 2, 2018.
Claims priority of provisional application 62/646,788, filed on Mar. 22, 2018.
Claims priority of provisional application 62/613,545, filed on Jan. 4, 2018.
Claims priority of provisional application 62/613,564, filed on Jan. 4, 2018.
Prior Publication US 2023/0159657 A1, May 25, 2023
Int. Cl. C07K 16/36 (2006.01); A61K 31/713 (2006.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/36 (2013.01) [A61K 31/713 (2013.01); A61K 47/68031 (2023.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61P 27/02 (2018.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 11 Claims
 
1. An antibody which binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody comprises a VH-CDR1, a VH-CDR2, and a VH-CDR3 comprising the amino acid sequences of the VH-CDR1, the VH-CDR2, and the VH-CDR3, respectively, as set forth in a VH comprising the amino acid sequence of SEQ ID NO: 151, and a VL-CDR1, a VL-CDR2, and a VL-CDR3 comprising the amino acid sequences of the VL-CDR1, the VL-CDR2, and the VL-CDR3, respectively, as set forth in a VL comprising the amino acid sequence of SEQ ID NO: 152.